| COMPANY |
Lantheus Holdings, Inc. |
| COURT |
United States District Court for the Southern District of New York |
| CASE NUMBER |
1:25-cv-07491 |
| JUDGE |
Honorable Jennifer H. Rearden |
| CLASS PERIOD |
February 26, 2025, through August 5, 2025 |
| SECURITY TYPE |
Securities |
LEAD PLAINTIFF DEADLINE IS NOVEMBER 10, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”).
Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Lantheus’ key Radiopharmaceutical Oncology product is PYLARIFY, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.
The Class Period begins on February 26, 2025, when Lantheus conducted an earnings call in conjunction with the issuance of the company’s fourth quarter and full-year results for fiscal 2024. During the call, Lantheus touted its financial results and PYLARIFY’s performance, including noting that “[w]ith over $1 billion in sales, PYLARIFY remains the clear #1 utilized PSMA PET imaging agent. We plan to build on this success by growing both volume and net sales in 2025 and are confident that we will maintain our market leadership and relative price premium, even amidst competitive pressures.” Likewise, Lantheus stated that the company estimated that full year net revenue would increase by 1% to 5% over 2024, with PYLARIFY expected to grow low to mid-single digits on a net basis.
On August 6, 2025, Lantheus announced disappointing second quarter 2025 financial results, revealing EPS and revenue figures that missed expectations. Lantheus also disclosed poor results for PYLARIFY, reporting “$250.6 million of sales, down 8.3%, lower than previously expected.” Lantheus attributed PYLARIFY’s results to the company having to navigate “increased competition in the PSMA PET landscape, which impacted PYLARIFY performance” and PYLARIFY continuing “to be concentrated in large institutions that due to constraints continued to grow at a slower rate than the overall market.” In addition, Lantheus lowered its full year 2025 revenue guidance and its full year 2025 adjusted fully diluted EPS guidance. On this news, Lantheus' stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lantheus provided investors with misleading statements concerning the true state of PYLARIFY’s competitive position, notably, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for PYLARIFY; (2) Lantheus failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking PYLARIFY's price point, revenue, and overall growth potential; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.